Author holds a concentrated HROW position (95% plus margin) and argues VEVYE's new CVS Caremark preferred coverage will drive market share and margin expansion.
HROW — LONG Author holds 95% of portfolio in HROW with 25% margin leverage, arguing the company is a '1-ft hurdle' they understand well. In November HROW announced its drug VEVYE won preferred status coverage on CVS Caremark, the largest US pharmacy benefit manager, so starting January 1st patients previously prescribed Xiidra will automatically receive VEVYE instead. HROW previously had no mainstream insurance coverage yet won 12% market share with cash-pay customers at $59/month; with insurance, sales figures are upwards of $200, so profit margins will more than 4x on the product, and the author expects the company could approach 20% market share this year. Main risk is extreme concentration and margin leverage.
They announced in November that their biggest drug, VEVYE, won preferred status coverage on the largest pharmacy benefit manager in the US - CVS Caremark. Starting January 1st this year, anyone on their coverage who was previously prescribed Xiidra will now automatically be given VEVYE instead.
This Reddit post, published January 19, 2026, features u/conangreer18 discussing HROW. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/conangreer18 · Tickers: HROW